US equities
|
AAPL
$332.30
▼-1.78%
MU
$860.53
▲+3.23%
NVDA
$208.25
▲+3.06%
AMD
$489.43
▲+4.84%
SNDK
$1,128.81
▲+5.00%
ORCL
$124.59
▲+4.50%
PLTR
$170.11
▼-4.61%
SPCX
$140.72
▲+3.19%
AAPL
$332.30
▼-1.78%
MU
$860.53
▲+3.23%
NVDA
$208.25
▲+3.06%
AMD
$489.43
▲+4.84%
SNDK
$1,128.81
▲+5.00%
ORCL
$124.59
▲+4.50%
PLTR
$170.11
▼-4.61%
SPCX
$140.72
▲+3.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Bioventus Inc. - Class A Common Stock
(NQ:
BVS
)
11.09
-2.06 (-15.67%)
Delayed Quote
Updated: 10:12 AM EST, Nov 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bioventus Inc. - Class A Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Bioventus Inc. (BVS) Q3 2021 Earnings Call Transcript
↗
November 10, 2021
BVS earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Will a Powerful Acquisition Make This Early 2021 IPO a Buy?
↗
August 17, 2021
Maybe the equivalent of an extra full quarter of revenue will get the attention of investors.
Via
The Motley Fool
Topics
Initial Public Offering
Bioventus Inc. (BVS) Q2 2021 Earnings Call Transcript
↗
August 11, 2021
BVS earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Bioventus Scoops Up Misonix In $518M Stock & Cash Deal; Raises FY21 Sales Outlook
↗
July 30, 2021
Recently listed Bioventus Inc (NASDAQ: BVS) has agreed to acquire Misonix Inc (NASDAQ: MSON) for $518 million in a cash-and-stock transaction. Misonix...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 1, 2021
↗
July 01, 2021
Upgrades Citigroup upgraded the previous rating for Thor Industries Inc (NYSE:
Via
Benzinga
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
↗
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Earnings Scheduled For August 10, 2021
↗
August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
↗
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
↗
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Earnings Scheduled For May 12, 2021
↗
May 12, 2021
Companies Reporting Before The Bell • PolyPid (NASDAQ:PYPD) is estimated to report earnings for its first quarter. • Boyd Gaming (NYSE:BYD) is projected to report...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
